+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID06782412

Trial to Validate 18FAlF-FAPI-74 PETCT Imaging in Detecting Oesophagogastric and Pancreatic Cancers and Complex Cases

Led by KU Leuven · Updated on 2025-02-07

109

Participants Needed

3

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the detection ability of a new imaging method called 18FAlF-FAPI-74 PETCT compared to existing techniques like 18FFDG PETCT or conventional imaging in newly diagnosed patients with oesophagogastric adenocarcinoma and pancreatic ductal adenocarcinoma. The goal is to show that this method can better detect cancer in treatment-naive patients and to understand its usefulness in challenging cancer cases. This study is a multicenter trial sponsored by KU Leuven and covers patients with specific clinical stages of these cancers. Participants will undergo 18FAlF-FAPI-74 PETCT scans at designated medical centers. The procedure involves fasting for four hours before the scan, followed by intravenous injection of the imaging agent. After a 60-minute wait, a PETCT scan is performed, including a low-dose CT with oral contrast. Patients will be observed after the scan for any adverse events and asked to complete patient-reported outcomes. If a patient receives neo-adjuvant therapy, additional scans may be done before surgery, with the possibility of a third scan if surgery is delayed. Throughout the study, participants will be monitored from enrollment through 12 months after their first 18FAlF-FAPI-74 PETCT. Researchers will assess detection rates, diagnostic accuracy, impact on cancer staging and treatment plans, psychological effects, and adverse events. Detailed analyses include uptake measurements and correlation with pathology. This thorough follow-up aims to provide clear information on the value and safety of this imaging method in cancer care.

CONDITIONS

Brief Title

Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here